Kaymakoglu, SabahattinOğuz, DilekGür, GürdenGürel, SelimTankurt, EthemErsöz, GalipÖzenirler, SerenKalaycı, CemPoturoğlu, ŞuleÇakaloğlu, YılmazOkten, Atilla2024-11-082024-11-082007-08-010066-4804https://doi.org/10.1128/AAC.00088-07https://journals.asm.org/doi/10.1128/aac.00088-07https://hdl.handle.net/11452/47592Forty-eight hepatitis B virus (HBV) E antigen-negative chronic hepatitis B patients received pegylated interferon alfa-2b either alone or with lamivudine for 48 weeks and were followed for an additional 24 weeks. At the end of follow-up, virological response rates (HBV DNA levels of < 400 copies/ml) were similar in the monotherapy (24%) and combination therapy (26%) groups.eninfo:eu-repo/semantics/openAccessMicrobiologyPharmacology & pharmacyArticle0002485237000563020302251810.1128/AAC.00088-07